Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-17
2009-11-24
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S109000, C544S357000, C514S232500, C514S252110, C514S316000, C514S338000, C514S393000, C546S187000, C546S190000, C548S303100, C549S268000
Reexamination Certificate
active
07622497
ABSTRACT:
The present invention is directed to novel derivatives of gambogic acid and analogs thereof. The present invention also relates to the discovery that novel derivatives of gambogic acid are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 3989816 (1976-11-01), Rajadhyaksha
patent: 4444762 (1984-04-01), Rajadhyaksha
patent: 6335429 (2002-01-01), Cai et al.
patent: 6462041 (2002-10-01), Cai et al.
patent: 6613762 (2003-09-01), Cai et al.
patent: 7176234 (2007-02-01), Cai et al.
patent: WO 00/44216 (2000-08-01), None
patent: WO 2004/002428 (2004-01-01), None
Adawadkar, P.D. et al., “Colouring Matters ofGarcinia morella: Part VIII—Morellinol, Dihydromorelloflavone and Morelloflavone-7″-β-glucoside,”Indian J. Chem. 14B:19-21, Council of Scientific & Industrial Research (1976).
Adjei, A.A. et al., “Synergy of the Protein Farnesyltransferase Inhibitor SCH66336 and Cisplatin in Human Cancer Cell Lines,”Clin. Cancer Res. 7:1438-1445, American Association for Cancer Research, Inc. (2001).
Ahmad, S.A. et al., “Gamboge. Part II,”J. Chem. Soc. (C):772-779, The Chemical Society (1966).
Almond, J.B. and Cohen, G.M., “The proteasome: a novel target for cancer chemotherapy,”Leukemia 16:433-443, Nature Publishing Group (Apr. 2002).
Asano, J. et al., “Cytotoxic Xanthones fromGarcinia hanburyI,” Phytochem. 41:815-820, Elsevier Science Ltd. (1996).
Batteux, F. et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, The American Association of Immunologists (1999).
Bhat, H.B. et al., “The Colouring Matters ofGarcinia morella: Part V—Isolation of Desoxymorellin & Dihydroisomorellin,”Indian J. Chem. 2:405-410, The Council of Scientific & Industrial Research (1964).
Blanke, C.D., “Celecoxib With Chemotherapy in Colorectal Cancer,”Oncology(Huntingt) 16(No. 4 Suppl. 3):17-21 (Apr. 2002).
Boirivant, M. et al., “Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastroenterology 116:557-565, American Gastroenterological Association (1999).
Cao, S.-G. et al., “Novel Cytotoxic Polyprenylated Xanthonoids fromGarcinia gaudichaudii(Guttiferae),”Tetrahedron 54:10915-10924, Elsevier Science Ltd. (1998).
Cao, S.-G. et al., “Cytotoxic Caged Tetraprenylated Xanthonoids fromGarcinia gaudichaudii(Guttiferae),”Tetrahedron Lett. 39:3353-3356, Elsevier Science Ltd. (1998).
Chinnaiyan, A.M. et al., “The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication,”Nat. Med. 3:333-337, Nature Publishing Company (1997).
Coven, T.R. et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed. 15:22-27, Blackwell Munksgaard (1999).
Crawford, K.W. and Bowen, W.D., “Sigma-2 Receptor Agonists Activate a Novel Apoptotic Pathway and Potentiate Antineoplastic Drugs in Breast Tumor Cell Lines,”Can. Res. 62:313-322, American Association for Cancer Research, Inc. (Jan. 2002).
Database Biosis, Accession No. PREV199191109495, Qu, B.-X. et al., “The Experimental Studies on Antineoplastic Action of Gambogic II,” one page (1991).
Giermasz, A. et al., “Potentiating Antitumor Effects of a Combination Therapy with Lovastatin and Butyrate in the Lewis Lung Carcinoma Model in Mice,”Int. J. Cancer 97:746-750, Wiley-Liss, Inc. (Feb. 2002).
Heenen, M. et al., “Methotrexate induces apoptotic cell death in human keratinocytes,”Arch. Dermatol. Res. 290:240-245, Springer-Verlag (1998).
Infante, A.J. et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Pediatr. 133:629-633, Mosby, Inc. (1998).
Kalemkerian, G.P. and Ou, X., “Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines,”Cancer Chemother. Pharmacol. 43:145-150, Springer-Verlag (1999).
Karanjgaonkar, C.G. et al., “Morellic, Isomorellic and Gambogic Acids,”Tetrahedron Letts. 7:687-691, Pergamon Press Ltd. (1966).
Kelland, L.R. et al., “Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer,”Clin. Cancer Res. 7:3544-3550, American Association for Cancer Research, Inc. (2001).
Kyprianou, N. and Benning, C.M., “Suppression of Human Prostate Cancer Cell Growth By α1-Adrenoceptor Antagonists Doxazosin and Terazosin via Induction of Apoptosis,”Cancer Res. 60:4550-4555, American Association for Cancer Research, Inc. (2000).
Leong, Y.-W. et al., “Forbesione, a Modified Xanthone fromGarcinia forbesii,” J. Chem. Res. (S).:392-393, The Royal Society of Chemistry (1996).
Lin, L.-J. et al., “Isogambogic Acid and Isomorellinol fromGarcinia hanburyi,” Magn. Reson. Chem. 31:340-347, John Wiley & Sons, Ltd. (1993).
Liu, W.M. et al., “The in vitro activity of the tyrosine kinase inhibitor ST1571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents,”Br. J. Cancer 86:1472-1478, Nature Publishing Group (May 2002).
López-Hoyos, M. et al., “Regulation of B cell apoptosis by Bcl-2 and Bcl-XLand its role in the development of autoimmune diseases (Review),”Int. J. Mol. Med. 1:475-483, D. A. Spandidos (1998).
Lu, G.B. et al., “Isolation and Structure of Neo-gambogic Acid from Gamboge (Garcinia hanburryi),”Yao Hsueh Hsueh Pao 19:636-639, The Chinese Pharmaceutical Association and The Institute of Materia Medica (1984).
Motwani, M. et al., “Augmentation of Apoptosis and Tumor Regression by Flavopiridol in the Presence of CPT-11 in Hct116 Colon Cancer Monolayers and Xenografts,”Clin. Cancer Res. 7:4209-4219, American Association for Cancer Research, Inc. (2001).
Ohsako, S. and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Nature Publishing Group (1999).
Ollis, W.D. et al., “The Constitution of Gambogic Acid,”Tetrahedron 21:1453-1470, Pergamon Press Ltd. (1965).
O'Reilly, L.A. & Strasser, A., “Review: Apoptosis and autoimmune disease,”Inflamm. Res. 48:5-21, Birkhäuser Verlag, Basel (1999).
Ozawa, M. et al., “312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions,”J. Exp. Med. 189:711-718, The Rockefeller University Press (1999).
Qu, B.-X. et al., “The Experimental Studies on Antineoplastic Action of Gambogic II,”Zhongguo Zhongliu Linchuang 18:50-52, Tianjin: Tianjin-shi Yixue Zazhi She (1991).
Rao, G.S.R. et al., “Structure of moreollin, a pigment isolated fromGarcinia morellaDesser,”Proc. Indian Acad. Sci. 87A:75-86, The Indian Academy of Sciences (1978).
Regar, E. et al., “Stent development and local drug delivery,”Br. Med. Bull. 59:227-248, Oxford University Press (2001).
Rukachaisirikul, V. et al., “Caged-Tetraprenylated Xanthones fromGarcinia scortechinii,” Tetrahedron 56:8539-8543, Elsevier Science Ltd. (2000).
Savill, J., “Apoptosis in resolution of inflammation,”J. Leukoc. Biol. 61:375-380, Society for Leukocyte Biology (1997).
Sgadari, C. et al., “HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma,”Nat. Med. 8:225-232, Nature America Inc. (Mar. 2002).
Tai, D.-I. et al., “Activation of Nuclear Factor
Cai Sui Xiong
Jiang Songchun
Zhang Han-Zhong
Coppins Janet L
Cytovia, Inc.
Saeed Kamal A
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Derivatives of gambogic acid and analogs as activators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of gambogic acid and analogs as activators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of gambogic acid and analogs as activators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4053107